Acambis, Cambridge Biostability, Invitrogen deal

ACM granted Cambridge Biostability exclusive worldwide rights to an enterotoxigenic E. coli (ETEC) vaccine. ACM has completed four Phase I trials of a precursor to the HolaVax-ETEC vaccine. Cambridge plans to conduct trials of the vaccine this year and in 2006. ACM has an option to negotiate an exclusive license to market and sell the vaccine in North America. Financial terms were not disclosed. ...